News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Celgene (CELG) Release: Oral OTEZLA® (Apremilast) Demonstrated Clinically Meaningful And Sustained Improvements In Skin, Nail And Scalp Of Adult Patients With Moderate To Severe Plaque Psoriasis


3/24/2014 9:11:55 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

SUMMIT, N.J.--(BUSINESS WIRE)--Celgene Corporation (NASDAQ:CELG) today released new research findings on OTEZLA® (apremilast), the Company’s oral, selective inhibitor of phosphodiesterase 4 (PDE4), from the ESTEEM 1 and 2 phase III studies in patients with moderate to severe plaque psoriasis at the 72nd Annual Meeting of the American Academy of Dermatology (AAD) Annual Meeting in Denver, CO.

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com

comments powered by Disqus
Celgene
 
 
Psoriasis

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES